Shots:
- The US FDA has approved the PMA application of Womed Leaf for women undergoing hysteroscopic surgery for symptomatic moderate to severe intrauterine adhesions (Asherman syndrome); commercial launch expected in early 2026
- Womed Leaf was evaluated in the PREG2 trial (n=160) for mod. to sev. intrauterine adhesions, showing reduced severity of intrauterine adhesion after hysteroscopic adhesiolysis compared to no prevention method, with favorable safety
- Womed Leaf is made from Womed’s novel polymer, inserted post-uterine procedure to prevent uterine wall adhesion by expanding before natural discharge
Ref: Businesswire | Image: Womed | Press Release
Related News:- Womed Collaborates with Kebomed Europe & Saesco Medical to Launch Womed Leaf in Europe
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
